Drug intelligence / Profile preview

BTK inhibitor + fludarabine + CAR-T-CD19

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Oral, Intravenous

Overview

This combination involves a **Bruton's tyrosine kinase (BTK) inhibitor**, **fludarabine**, and **CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy**. BTK inhibitors are used to block B-cell receptor signaling, crucial for B-cell survival and proliferation. Fludarabine is a chemotherapy agent used to deplete lymphocytes before CAR-T cell infusion. CAR-T-CD19 therapy involves genetically modified T cells that target CD19-expressing B cells, commonly used in treating B-cell malignancies like lymphomas and leukemias.

Targets

DNACD19 (B lymphocyte antigen CD19)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on BTK inhibitor + fludarabine + CAR-T-CD19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTK inhibitor + fludarabine + CAR-T-CD19.

Explore the full profile